Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXACT SCIENCES CORPEXAS · Entity 56619 | Director | June 02, 2021 | June 03, 2021 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXACT SCIENCES CORP
Report date June 02, 2021 · Filed June 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,292 |
Reported balance
After 2001-06-02 transaction · row 1
1 source rowRow 1 · 2001-06-02 · Sale · Disposed 17,000 · Balance 5,292 F1: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan.
STANDARD BIOTOOLS INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 344,456 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 99,116 · Balance 344,456 F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2036-06-18 | Direct | 263,884 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 263,884 · Balance 263,884 F2: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
F2: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SomaLogic, Inc.
Report date January 05, 2024 · Filed January 10, 2024
Section 16 reporting ended · disclosed 2024-01-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-05 · Disposition to issuer · Disposed 185,400 · Balance 0 F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and
F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"),
F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to buy) · Derivative | 263,884 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001193125-26-279834 · ownership.xml · derivative · entry 2 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,884 Underlying: Common Stock · 263,884 shares Expires 2036-06-18 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 99,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279834 · ownership.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,456 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 00:31 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 51,282 | $1.17 | $59,999.94 |
DisclosureSEC source: 0001193125-26-086154 · ownership.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,340 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2026, subject to the Reporting Person's continued service through the applicable vesting date. F2 · balance_after: The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $60,000 in cash compensation for certain services as a board member. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to buy) · Derivative | 188,490 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0000950170-25-089653 · ownership.xml · derivative · entry 2 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,490 Underlying: Common Stock · 188,490 shares Expires 2035-06-20 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly installments beginning on July 20, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:58 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 94,592 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089653 · ownership.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,058 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 20, 2026 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:52 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 56,338 | $1.07 | $59,999.97 |
DisclosureSEC source: 0000950170-25-032559 · ownership.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,466 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date. F2 · balance_after: The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $60,000 in cash compensation for certain services as a board member. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 21:16 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to buy) · Derivative | 108,319 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000950170-24-080717 · ownership.xml · derivative · entry 2 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,319 Underlying: Common Stock · 108,319 shares Expires 2034-06-28 F3 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly installments beginning on July 28, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 21:16 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 43,128 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-080717 · ownership.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,128 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 28, 2025 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. F2 · balance_after: The Reporting Person declined and forfeited the 79,412 RSUs previously granted to the Reporting Person on January 5, 2024 in connection with the transactions contemplated by the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc., Martis Merger Sub, Inc. and SomaLogic, Inc. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:05 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to buy) · Derivative | 205,794 | Not disclosed Strike: $2.47 | Not disclosed |
DisclosureSEC source: 0001104659-24-002652 · tm242400-5_4seq1.xml · derivative · entry 2 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,794 Underlying: Common Stock · 205,794 shares Expires 2033-06-07 F3 · price: Pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic, Inc. ("Soma Logic") (the "Merger"), each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 (the "Exchange Ratio") rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. F4 · price: Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F2 · derivative.exercise_date: 25% of the shares underlying the option vest on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:05 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 79,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-002652 · tm242400-5_4seq1.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,412 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in four equal annual installments beginning January 5, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:18 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (right to buy) · Derivative | 185,400 | Not disclosed Strike: $2.74 | Not disclosed |
DisclosureSEC source: 0001209191-24-001312 · doc4.xml · derivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,400 shares Expires 2033-06-07 F2 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3 · price: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4 · price: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F1 · derivative.exercise_date: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| June 08, 2023 Filed Jun 13, 2023 01:12 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 185,400 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-23-036534 · doc4.xml · derivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,400 Underlying: Common Stock · 185,400 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests as to 1/4 of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vest monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| October 22, 2020 Filed Oct 23, 2020 16:44 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 420 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055687 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,292 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 17:21 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 15,620 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-20-044761 · doc4.xml · derivative · entry 3 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,620 shares Expires 2023-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 17:21 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 30,620 | $94.00 | $2,878,280.00 |
DisclosureSEC source: 0001209191-20-044761 · doc4.xml · nonDerivative · entry 2 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,872 F2 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 17:21 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 15,620 | $9.24 | $144,328.80 |
DisclosureSEC source: 0001209191-20-044761 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 16:28 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 2,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043596 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,872 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 457 | $120.19 | $54,926.83 |
DisclosureSEC source: 0001209191-19-044243 · doc4.xml · nonDerivative · entry 6 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,181 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2018 to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.13 to $120.24, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 2,770 | $119.30 | $330,461.00 |
DisclosureSEC source: 0001209191-19-044243 · doc4.xml · nonDerivative · entry 5 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,638 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2018 to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.85 to $119.80, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 2,436 | $118.21 | $287,959.56 |
DisclosureSEC source: 0001209191-19-044243 · doc4.xml · nonDerivative · entry 4 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,408 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2018 to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.81 to $118.80, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,200 | $117.33 | $140,796.00 |
DisclosureSEC source: 0001209191-19-044243 · doc4.xml · nonDerivative · entry 3 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,844 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2018 to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.72 to $117.72, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,800 | $115.89 | $208,602.00 |
DisclosureSEC source: 0001209191-19-044243 · doc4.xml · nonDerivative · entry 2 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,044 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2018 to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.52 to $116.24, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 1,337 | $114.99 | $153,741.63 |
DisclosureSEC source: 0001209191-19-044243 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,844 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 26, 2018 to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.51 to $115.34, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 16:57 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 2,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043373 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,181 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 17:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 7,500 | $96.00 | $720,000.00 |
DisclosureSEC source: 0001209191-19-015109 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,483 F1 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 17:04 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 3,427 | $58.86 | $201,713.22 |
DisclosureSEC source: 0001209191-18-044761 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,983 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 19:32 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantDeferred Stock Units · Derivative | 3,230 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-044479 · doc4.xml · derivative · entry 2 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 Underlying: Common Stock · 3,230 shares Expires not disclosed F1 · security: Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy. Each deferred stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service. F2 · derivative.expiration_date: These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 200 | $40.84 | $8,167.60 |
DisclosureSEC source: 0001209191-18-024727 · doc4.xml · nonDerivative · entry 2 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,410 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.69 to $40.985, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 8,248 | $39.70 | $327,462.10 |
DisclosureSEC source: 0001209191-18-024727 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,610 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.34 to $40.23, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 17, 2017 Filed Aug 18, 2017 16:07 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | PurchaseCommon Stock | 2,500 | $37.71 | $94,275.00 |
DisclosureSEC source: 0001209191-17-049599 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,858 Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 17:18 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 6,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046726 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,358 F1 · security: These shares of restricted stock were issuesd pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 02, 2001 Filed Jun 3, 2021 16:03 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 17,000 | $108.11 | $1,837,870.00 |
DisclosureSEC source: 0001209191-21-037602 · doc4.xml · nonDerivative · entry 1 Carey Thomas D. · CIK 0001574633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,292 F1 · acquired: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.